Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion

• Etienne Lengline,
• Kheïra Beldjord,
• Hervé Dombret,
• Jean Soulier,
• Nicolas Boissel,
• Emmanuelle Clappier

Affiliations

Etienne Lengline

Adolescents and Young Adults Hematology Unit, APHP, Saint-Louis Hospital, Paris, France;EA-3518, Institute of Hematology (IUH), Univ Paris Diderot, Sorbonne Paris Cité, France

Kheïra Beldjord

Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France

Hervé Dombret

Adolescents and Young Adults Hematology Unit, APHP, Saint-Louis Hospital, Paris, France;EA-3518, Institute of Hematology (IUH), Univ Paris Diderot, Sorbonne Paris Cité, France

Jean Soulier

Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France;U944 INSERM, Institute of Hematology (IUH), Univ Paris Diderot, Sorbonne Paris Cité, France

Nicolas Boissel

Adolescents and Young Adults Hematology Unit, APHP, Saint-Louis Hospital, Paris, France;EA-3518, Institute of Hematology (IUH), Univ Paris Diderot, Sorbonne Paris Cité, France

Emmanuelle Clappier

Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France;U944 INSERM, Institute of Hematology (IUH), Univ Paris Diderot, Sorbonne Paris Cité, France;Department of Genetics, Robert Debré Hospital, Paris, France